These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18270717)

  • 21. Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
    Hamilton LJ; Evans AJ; Wilson AR; Scott N; Cornford EJ; Pinder SE; Khan HN; Macmillan RD
    Clin Radiol; 2004 Oct; 59(10):895-902. PubMed ID: 15451348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
    Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
    Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
    Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
    Saadatmand S; Obdeijn IM; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Woldringh GH; Bergers E; Verhoef C; Heijnsdijk EA; Hooning MJ; de Koning HJ; Tilanus-Linthorst MM
    Int J Cancer; 2015 Oct; 137(7):1729-38. PubMed ID: 25820931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk.
    Podo F; Sardanelli F; Canese R; D'Agnolo G; Natali PG; Crecco M; Grandinetti ML; Musumeci R; Trecate G; Bergonzi S; De Simone T; Costa C; Pasini B; Manuokian S; Spatti GB; Vergnaghi D; Morassut S; Boiocchi M; Dolcetti R; Viel A; De Giacomi C; Veronesi A; Coran F; Silingardi V; Turchett D; Cortesi L; De Santis M; Federico M; Romagnoli R; Ferrari S; Bevilacqua G; Bartolozzi C; Caligo MA; Cilotti A; Marini C; Cirillo S; Marra V; Martincich L; Contegiacomo A; Pensabene M; Capuano I; Burgazzi GB; Petrillo A; Bonomo L; Carriero A; Mariani-Costantini R; Battista P; Cama A; Palca G; Di Maggio C; D'Andrea E; Bazzocchi M; Francescutti GE; Zuiani C; Londero V; Zunnui I; Gustavino C; Centurioni MG; Iozzelli A; Panizza P; Del Maschio A
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):115-24. PubMed ID: 12585665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
    Calderon-Margalit R; Paltiel O
    Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammographic, US, and MR imaging phenotypes of familial breast cancer.
    Schrading S; Kuhl CK
    Radiology; 2008 Jan; 246(1):58-70. PubMed ID: 18096529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.
    Le-Petross HT; Whitman GJ; Atchley DP; Yuan Y; Gutierrez-Barrera A; Hortobagyi GN; Litton JK; Arun BK
    Cancer; 2011 Sep; 117(17):3900-7. PubMed ID: 21365619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
    Hagen AI; Kvistad KA; Maehle L; Holmen MM; Aase H; Styr B; Vabø A; Apold J; Skaane P; Møller P
    Breast; 2007 Aug; 16(4):367-74. PubMed ID: 17317184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
    Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
    Kolben T; Hary T; Holdt LM; Schwarz TM; Goess C; Wuerstlein R; Gallwas J; Toth B; Weissenbacher T; Jeschke U; Harbeck N; Ditsch N
    Anticancer Res; 2016 Jun; 36(6):3185-90. PubMed ID: 27272846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
    Zhang J; Sun J; Ouyang T; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):185-9. PubMed ID: 26988823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of interval breast malignancies in patients with BRCA mutations.
    Komenaka IK; Ditkoff BA; Joseph KA; Russo D; Gorroochurn P; Ward M; Horowitz E; El-Tamer MB; Schnabel FR
    Cancer; 2004 May; 100(10):2079-83. PubMed ID: 15139048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy?
    Burness ML; Olopade OI
    J Clin Oncol; 2011 May; 29(13):1652-4. PubMed ID: 21444875
    [No Abstract]   [Full Text] [Related]  

  • 40. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.